@article{39fed66549414b96845b3ada5a09dc24,
title = "Endurance and gait speed relationships with mild cognitive impairment and dementia",
abstract = "Introduction: Slower mobility is associated with mild cognitive impairment (MCI) and dementia. We examined the interaction of endurance with gait speed on prevalent MCI and dementia. Methods: Cross-sectional multinomial regression in the ARIC cohort (n = 2844 participants; 71 to 94 years; 44% men; 18% Black persons) with cognitive status (normal/MCI/dementia), 4 m gait speed, and endurance (2 minute walk [2MW]). Results: Faster gait speed (up to but not above 1 m/s) and better 2MW were separately associated with lower dementia risk. Good performance in both (2MW = 200 m, gait speed = 1.2 m/s) was associated with 99% lower dementia (Relative Prevalence Ratio [RPR] = 0.01 [95% CI: 0.0 to 0.06]) and 73% lower MCI, RPR = 0.27 (0.15 to 0.48) compared to poor performance in both (2MW = 100 m, gait speed = 0.8 m/s). Models incorporating a gait speed-by-2MW interaction term outperformed gait speed-only models (P <.001). Discussion: Gait speed relationships with dementia diminish at faster gait speeds. Combining endurance with gait speed may yield more sensitive markers of MCI and dementia than gait speed alone.",
keywords = "cognition, dementia, endurance, mild cognitive impairment, walking speed",
author = "Windham, {Beverly Gwen} and Parker, {Sara B.} and Xiaoqian Zhu and Gabriel, {Kelley Pettee} and Priya Palta and Sullivan, {Kevin J.} and Parker, {Kirby G.} and Knopman, {David S.} and Gottesman, {Rebecca F.} and Griswold, {Michael E.} and Mosley, {Thomas H.}",
note = "Funding Information: Dr. Knopman served on a Data Safety Monitoring Board for the DIAN study. He serves on a Data Safety Monitoring Board for a tau therapeutic for Biogen, but receives no personal compensation. He is an investigator in a clinical trial sponsored by Lilly Pharmaceuticals and the University of Southern California. He serves as a consultant for Samus Therapeutics, Third Rock and Alzeca Biosciences but receives no personal compensation. Drs. Windham, Knopman, Gabriel, Palta, Gottesman, Griswold, and Mosley receive grant funding from the National Institutes of Health. The other authors have no conflicts of interest to disclose. Funding Information: The authors thank the staff and participants of the ARIC study for their important contributions. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, HHSN268201700005I). Neurocognitive data were collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD), and with previous brain MRI examinations funded by R01‐HL70825 from the NHLBI. The authors thank the staff and participants of the ARIC study for their important contributions. S. Parker and K. Parker are supported by the Medical Student Training in Aging Research Grant through National Institute on Aging (5T35AG038027‐06) American Federation for Aging Research and the Hearin Foundation, University of Mississippi Medical Center (UMMC) Medical Student Research Program. P. Palta is supported by grant R00AG052830 from the National Institute on Aging. Publisher Copyright: {\textcopyright} 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.",
year = "2022",
doi = "10.1002/dad2.12281",
language = "English (US)",
volume = "14",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "1",
}